These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17584045)

  • 1. Peroxisome proliferator-activated receptor-gamma in vascular biology.
    Li J; Wang N
    Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):109-17. PubMed ID: 17584045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones--tools for the research of metabolic syndrome X.
    Komers R; Vrána A
    Physiol Res; 1998; 47(4):215-25. PubMed ID: 9803467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?
    Ketsawatsomkron P; Pelham CJ; Groh S; Keen HL; Faraci FM; Sigmund CD
    J Biol Chem; 2010 Mar; 285(13):9311-9316. PubMed ID: 20129921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update.
    Wang N; Yin R; Liu Y; Mao G; Xi F
    Circ J; 2011; 75(3):528-35. PubMed ID: 21325726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors and cardiovascular remodeling.
    Schiffrin EL
    Am J Physiol Heart Circ Physiol; 2005 Mar; 288(3):H1037-43. PubMed ID: 15374828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
    Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
    Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and additional vascular effects of thiazolidinediones.
    Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
    Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes.
    Hsueh WA; Jackson S; Law RE
    Diabetes Care; 2001 Feb; 24(2):392-7. PubMed ID: 11213897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
    El Midaoui A; Wu L; Wang R; de Champlain J
    Am J Hypertens; 2006 Apr; 19(4):407-12. PubMed ID: 16580578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.
    Biscetti F; Gaetani E; Flex A; Aprahamian T; Hopkins T; Straface G; Pecorini G; Stigliano E; Smith RC; Angelini F; Castellot JJ; Pola R
    Diabetes; 2008 May; 57(5):1394-404. PubMed ID: 18268046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PPAR in cardiovascular diseases.
    Das SK; Chakrabarti R
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):193-209. PubMed ID: 18221086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N; Walcher D
    Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.
    Guo L; Tabrizchi R
    Pharmacol Ther; 2006 Jul; 111(1):145-73. PubMed ID: 16305809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.
    Itoh H; Doi K; Tanaka T; Fukunaga Y; Hosoda K; Inoue G; Nishimura H; Yoshimasa Y; Yamori Y; Nakao K
    Clin Exp Pharmacol Physiol; 1999 Jul; 26(7):558-60. PubMed ID: 10405788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery.
    Ivanova EA; Parolari A; Myasoedova V; Melnichenko AA; Bobryshev YV; Orekhov AN
    J Cardiol; 2015 Oct; 66(4):271-8. PubMed ID: 26072262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases].
    Scheen AJ; Paquot N
    Rev Med Liege; 2005 Feb; 60(2):89-95. PubMed ID: 15819371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.